A detailed history of Alyeska Investment Group, L.P. transactions in In8 Bio, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 434,809 shares of INAB stock, worth $147,835. This represents 0.0% of its overall portfolio holdings.

Number of Shares
434,809
Previous 641,008 32.17%
Holding current value
$147,835
Previous $544,000 78.49%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.27 - $0.88 $55,673 - $181,455
-206,199 Reduced 32.17%
434,809 $117,000
Q2 2024

Aug 14, 2024

BUY
$0.85 - $1.68 $165,743 - $327,586
194,992 Added 43.72%
641,008 $544,000
Q1 2024

May 15, 2024

SELL
$0.95 - $1.69 $354,973 - $631,478
-373,656 Reduced 45.59%
446,016 $526,000
Q4 2023

Feb 14, 2024

BUY
$0.69 - $2.34 $565,573 - $1.92 Million
819,672 New
819,672 $1.13 Million

Others Institutions Holding INAB

About IN8BIO, INC.


  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $8.33M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.